0000905718-18-000561.txt : 20180611
0000905718-18-000561.hdr.sgml : 20180611
20180611084240
ACCESSION NUMBER: 0000905718-18-000561
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180605
FILED AS OF DATE: 20180611
DATE AS OF CHANGE: 20180611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EMSTER KURT VON
CENTRAL INDEX KEY: 0001252524
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36500
FILM NUMBER: 18891021
MAIL ADDRESS:
STREET 1: 601 GATEWAY BOULEVARD
STREET 2: SUITE 350
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc.
CENTRAL INDEX KEY: 0001042074
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943103561
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7999 GATEWAY BLVD
STREET 2: SUITE 130
CITY: NEWARK
STATE: CA
ZIP: 94560
BUSINESS PHONE: 510-293-8800
MAIL ADDRESS:
STREET 1: 7999 GATEWAY BLVD
STREET 2: SUITE 130
CITY: NEWARK
STATE: CA
ZIP: 94560
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX, INC.
DATE OF NAME CHANGE: 20090721
FORMER COMPANY:
FORMER CONFORMED NAME: METABOLEX INC
DATE OF NAME CHANGE: 19970710
4/A
1
cymabayfm4a_jun52018.xml
OWNERSHIP DOCUMENT
X0306
4/A
2018-06-05
2018-06-07
0
0001042074
CymaBay Therapeutics, Inc.
CBAY
0001252524
EMSTER KURT VON
C/O CYMABAY THERAPEUTICS, INC.
7999 GATEWAY BLVD, SUITE 130
NEWARK
CA
94560
1
0
0
0
Common Stock
2018-06-05
4
X
0
2000
5.75
A
19236
I
By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock
2018-06-05
4
S
0
920
12.51
D
18316
I
By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Common Stock
90000
D
Common Stock
273417
I
See footnotes
Warrant (right to buy)
5.75
2018-06-05
4
X
0
2000
0
D
2013-09-30
2018-09-30
Common Stock
2000
0
I
By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
This amended Form 4 is being amended to correct the incorrect code used for acquisition of the warrant securities. On June 5, 2018, Kurt von Emster (the "Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share.
Shares are held by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE" together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth.
From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
/s/ John Heard, as attorney-in-fact
2018-06-11